Respiratory syncytial virus vaccine for adults marks a turning point
The candidate vaccine againstrespiratory syncytial virus (VRS)for people over 60 years of age that are being developed by different international groups for the pharmaceutical company GSK, and in which researchers from the Santiago Clinic participate, is called to be “a turning point for other vaccines and in the treatment of this disease in adults”. As … Read more